What AbbVie Inc.'s SEC filings said

10-Q for 2026Q3, filed 3 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Drug Pricing and Tariff Relief66 · importance in its document · 10-Q · 2026Q3
In January 2026, AbbVie announced a voluntary agreement with the U.S. government to advance access and affordability while protecting investment in U.S. pharmaceutical innovation. AbbVie will provide low prices in Medicaid and expand…
Outstanding Indebtedness64 · importance in its document · 10-Q · 2026Q3
AbbVie issued $18.0 billion aggregate principal of unsecured senior notes during the nine months ended September 30, 2026, and repaid $2.0 billion of a 364-day term loan and $2.0 billion of 3.20% senior notes. The company had no…
Guidance / Outlook62 · importance in its document · 8-K exhibit · 5 Oct 2026
AbbVie included $216 million of acquired in-process research and development (IPR&D) and milestones expense in third-quarter and full-year 2026 adjusted diluted EPS guidance. The expense reduced adjusted diluted EPS guidance by $0.11,…
Operating Income and Margins61 · importance in its document · 8-K exhibit · 30 Oct 2026
Third-quarter operating earnings were $6.267 billion, compared with $1.904 billion in the prior-year quarter. GAAP operating margin was 36.0%, while adjusted operating margin was 48.7%. Total operating costs and expenses declined to…
Guidance raised60 · rule score among filings · 8-K Item 2.02 · 30 Oct 2026
Raises 2026 Adjusted Diluted EPS Guidance Range from $13.76 - $13.96 to $13.95 - $13.99, which Includes an Unfavorable Impact of $0.69 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 3 Nov 2026

Full report · Filing on EDGAR

Drug Pricing and Tariff ReliefImportance 66
In January 2026, AbbVie announced a voluntary agreement with the U.S. government to advance access and affordability while protecting investment in U.S. pharmaceutical innovation. AbbVie will provide low prices in…
Outstanding IndebtednessImportance 64
AbbVie issued $18.0 billion aggregate principal of unsecured senior notes during the nine months ended September 30, 2026, and repaid $2.0 billion of a 364-day term loan and $2.0 billion of 3.20% senior notes. The…
Acquisition / Partnership / DivestitureImportance 59
AbbVie’s investing cash flows included $10.6 billion of net cash payments for business acquisitions, primarily the Apogee Therapeutics acquisition, during the nine months ended September 30, 2026. The period also…
Immunology Product Demand and ExpansionImportance 59
Skyrizi net revenues increased 23% in the third quarter and 25% in the first nine months of 2026, driven by continued strong market share uptake and market growth across indications. Rinvoq net revenues increased 24%…
Income Tax Rate ChangesImportance 57
AbbVie’s effective tax rate was 13% for the third quarter and 16% for the first nine months of 2026, compared with 74% and 39%, respectively, in 2025. The decreases primarily reflected a reduced impact from…
Revenue Performance and MixImportance 54
Worldwide net revenues for the nine months ended September 30, 2026 were $49.396 billion, up 10.9% reported and 10.1% at constant currency; U.S. revenue rose 9.9% to $37.163 billion and international revenue rose 14.0%…
Gross Margin DriversImportance 54
Gross margin was $13.119 billion for the three months and $36.602 billion for the nine months ended September 30, 2026, compared with $10.472 billion and $30.890 billion, respectively, in 2025. Gross margin as a…
Operating Expense TrendsImportance 54 · +1 more on this subject
SG&A expense was $4.087 billion for the third quarter and $11.297 billion for the first nine months of 2026, versus $3.569 billion and $10.115 billion in the corresponding 2025 periods. SG&A as a percentage of revenue…
Regulatory RiskImportance 53
The Inflation Reduction Act of 2022 has and will continue to have a significant impact on AbbVie’s business. In January 2026, CMS selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts…
Oncology Market PositionImportance 51
Venclexta net revenues increased 11% in the third quarter and 10% in the first nine months of 2026, primarily driven by increased demand. Elahere grew 31% and 23%, respectively, on increased demand, while Epkinly net…
Cash Flow and Capital AllocationImportance 49
Operating cash flow for the first nine months of 2026 was $14.871 billion, up from $13.812 billion in 2025, reflecting higher operating results and lower litigation payments, partly offset by working-capital timing and…
Neuroscience Market GrowthImportance 46
Vraylar net revenues increased 14% in the third quarter and 17% in the first nine months, reflecting market share uptake, market growth and favorable pricing. Botox Therapeutic increased 10% and 12%, respectively, with…

8-K filings last 12 months

Other officer change2 Nov 2026 · 8-K Item 5.02 · Routine · rule score 15
“On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent…”
Guidance raised30 Oct 2026 · 8-K Item 2.02 · Flagged · rule score 60
“Raises 2026 Adjusted Diluted EPS Guidance Range from $13.76 - $13.96 to $13.95 - $13.99, which Includes an Unfavorable Impact of $0.69 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third…”
Read from the attached exhibit: Operating Income and Margins · Product Launch and Transition · Guidance / Outlook
Board change15 Oct 2026 · 8-K Item 5.02 · Routine · rule score 10
“On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director.”
Results (release not read)5 Oct 2026 · 8-K Item 2.02 · Routine · rule score 20
Read from the attached exhibit: Guidance / Outlook
Press release attached to an 8-K3 Sept 2026 · 8-K
Read from the attached exhibit: Acquisition / Partnership / Divestiture · Guidance / Outlook · Product / Drug Pipeline Progress
Guidance revised (direction not stated)31 Jul 2026 · 8-K Item 2.02 · Flagged · rule score 55
“Updates 2026 Adjusted Diluted EPS Guidance Range from $13.91 - $14.11 to $13.87 - $14.07;”
Read from the attached exhibit: Acquisition / Partnership / Divestiture · Operating Expense Trends · Guidance / Outlook
Results, no stated guidance change6 Jul 2026 · 8-K Item 2.02 · Routine · rule score 10
Read from the attached exhibit: Guidance / Outlook
Press release attached to an 8-K22 Jun 2026 · 8-K
Read from the attached exhibit: Acquisition / Partnership / Divestiture · Guidance / Outlook · Product / Drug Pipeline Progress
Guidance raised29 Apr 2026 · 8-K Item 2.02 · Flagged · rule score 60
“Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28, which Includes an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the First…”
Results (release not read)3 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
Results (release not read)4 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20
Results (release not read)7 Jan 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

10-Q · 2026Q2filed 3 Aug 2026
Revenue Performance and Mix · Gross Margin Drivers · Income Tax Rate Changes

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.